Recent studies have highlighted the potential of Mesenchymal Stem Cells (MSCs) as an alternative treatment for Alopecia Areata (AA) due to their immunosuppressive properties. While MSCs have shown promise in cell experiments, their effectiveness in vivo remains uncertain. This study aims to validate local administration of MSC therapy’s efficacy in AA treatment through animal experiments. AA was induced through Interferon-gamma (IFN-γ) administration in mice, and MSC treatment (MSCT)’s effects were assessed visually and through tissue analysis. The MSC-treated group showed more hair regrowth compared to the control (CTL) group. MSCT notably reduced local inflammatory cytokines (JAK1, JAK2, STAT1, STAT3, IFN-γR, IL-1β, IL-16, IL-17α, and IL-18) in AA-induced mice’s skin, but systemic cytokine levels remained unchanged. Furthermore, MSC treatment normalized the expression of Wnt/β-catenin signaling pathway genes (LEF1 and β-catenin) and growth factors (FGF7 and FGF2), which are crucial for hair cycle regulation. This study lays the groundwork for further exploring MSCs as a potential treatment for AA, but more research is needed to fully understand their therapeutic potential.
Biologic agents are widely used for severe psoriasis and are generally safe, but infections may develop or worsen during therapy and mimic disease exacerbation. We report a 24-year-old woman with psoriasis treated with guselkumab who developed sudden, widespread worsening of oozing psoriasiform lesions. Skin biopsy revealed dermatophytosis consistent with tinea incognito. Three weeks of oral and topical antifungal therapy resolved the fungal infection, while residual psoriatic lesions continued to improve with guselkumab. Guselkumab has been continued for 1 year without recurrence or reinfection. Although baseline mycological testing was unavailable, the clinical course indicates that a pre-existing, clinically inapparent dermatophyte infection may have become clinically evident and spread extensively during guselkumab therapy. This case highlights the importance of considering fungal infections in patients receiving biologic therapy who develop atypical psoriasis worsening and supports early mycological evaluation when clinically indicated.
1 January 2025 in Journal of Korean Medical Science